Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM31OGF)

Drug Name
U0126 Drug Info
Synonyms
U0126; 109511-58-2; U-0126; U 0126; 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene; UNII-8027P94HLL; CHEBI:64208; 8027P94HLL; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile; FT-1069-1; 218601-62-8; Succinonitrile, bis(amino(o-aminophenylthio)methylene)-; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-; C18H16N6S2; (2z)-Bis{amino[(2-Aminophenyl)sulfanyl]methylidene}butanedinitrile; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile
Cross-matching ID
PubChem CID
3006531
ChEBI ID
CHEMBL34704
CAS Number
CAS 218601-62-8
TTD Drug ID
D0GD8Y

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.41 0.00e+0 93/133 (69.92%) COX7A1;NDUFA4L2;LHPP;...
Pyruvate metabolism 2.05 0.00e+0 41/47 (87.23%) PCK1;DLD;GRHPR;...
Citrate cycle (TCA cycle) 2.04 0.00e+0 30/30 (100%) ACO2;PCK1;DLD;...
Proximal tubule bicarbonate reclamation 2.01 4.11e-3 21/23 (91.3%) CA2;AQP1;ATP1A2;...
Glyoxylate and dicarboxylate metabolism 1.99 3.29e-3 23/30 (76.67%) GLUL;CAT;ACO2;...
Folate biosynthesis 1.95 2.74e-3 23/26 (88.46%) AKR1C3;SPR;FPGS;...
Ascorbate and aldarate metabolism 1.94 3.52e-3 15/30 (50%) ALDH3A2;ALDH2;RGN;...
Valine, leucine and isoleucine degradation 1.91 4.11e-3 42/48 (87.5%) ACAA2;ABAT;BCAT2;...
Parkinson disease 1.84 3.65e-3 176/249 (70.68%) COX7A1;NDUFA4L2;MAOA;...
Metabolism of xenobiotics by cytochrome P450 1.82 3.29e-3 49/77 (63.64%) AKR1C1;GSTM3;GSTA1;...
Fatty acid degradation 1.82 2.99e-3 40/43 (93.02%) ACAA2;ACADVL;ECI1;...
Ribosome 1.81 3.42e-3 113/158 (71.52%) RPS4Y1;MRPS16;RPS8;...
alpha-Linolenic acid metabolism 1.81 3.16e-3 17/25 (68%) PLAAT3;PLA2G2A;FADS2;...
Propanoate metabolism 1.81 2.94e-3 30/34 (88.24%) ABAT;DLD;LDHA;...
Steroid hormone biosynthesis 1.78 3.84e-3 43/61 (70.49%) AKR1C2;AKR1C3;AKR1C1;...
Tryptophan metabolism 1.74 6.16e-3 35/42 (83.33%) MAOA;CAT;DLD;...
Arginine biosynthesis 1.73 7.74e-3 17/22 (77.27%) ASS1;GLUL;GLUD1;...
Fat digestion and absorption 1.69 1.28e-2 35/43 (81.4%) PLA2G2A;SCARB1;PLPP1;...
Glycine, serine and threonine metabolism 1.69 1.34e-2 31/40 (77.5%) CBS;MAOA;GAMT;...
Thermogenesis 1.69 1.40e-2 173/232 (74.57%) COX7A1;NDUFA4L2;ADCY9;...
Amyotrophic lateral sclerosis 1.67 1.64e-2 267/364 (73.35%) NEFH;NEFM;COX7A1;...
Cysteine and methionine metabolism 1.67 1.83e-2 43/50 (86%) CBS;BHMT2;TST;...
Drug metabolism 1.66 1.89e-2 78/151 (51.66%) GSTM3;GSTA1;MAOA;...
Bile secretion 1.66 1.81e-2 68/90 (75.56%) CA2;AQP1;ATP1A2;...
Biosynthesis of unsaturated fatty acids 1.66 1.74e-2 21/27 (77.78%) FADS1;SCD;FADS2;...
Butanoate metabolism 1.61 3.32e-2 23/28 (82.14%) ABAT;BDH2;HADH;...
Alanine, aspartate and glutamate metabolism 1.59 3.99e-2 27/37 (72.97%) ASS1;GLUL;ABAT;...
Nitrogen metabolism 1.56 4.58e-2 16/17 (94.12%) CA2;GLUL;GLUD1;...
PPAR signaling pathway 1.56 4.56e-2 66/74 (89.19%) ADIPOQ;SCD;FADS2;...
Pentose and glucuronate interconversions 1.56 4.52e-2 17/34 (50%) DCXR;CRYL1;UGDH;...
Morphine addiction -1.65 4.22e-2 80/91 (87.91%) GNG10;GABRA5;GNAI3;...
Epithelial cell signaling in Helicobacter pylori infect... -1.66 3.61e-2 62/70 (88.57%) ADAM17;TJP1;ATP6V0B;...
B cell receptor signaling pathway -1.67 3.74e-2 71/81 (87.65%) SYK;GSK3B;CD19;...
Leishmaniasis -1.67 3.89e-2 67/77 (87.01%) HLA-DRB1;FCGR2A;ITGB2;...
Th17 cell differentiation -1.67 4.05e-2 95/107 (88.79%) PRKCQ;SMAD3;HLA-DRB1;...
Human T-cell leukemia virus 1 infection -1.68 4.01e-2 197/219 (89.95%) IL1R1;HLA-DOA;CREB5;...
Natural killer cell mediated cytotoxicity -1.70 3.73e-2 99/131 (75.57%) IFNAR2;CD244;FASLG;...
Parathyroid hormone synthesis, secretion and action -1.71 3.58e-2 98/106 (92.45%) CREB5;GNAI3;ATF4;...
Acute myeloid leukemia -1.72 3.32e-2 66/67 (98.51%) PIK3CD;TCF7L2;MAP2K1;...
Osteoclast differentiation -1.73 3.30e-2 117/127 (92.13%) LILRB1;IL1R1;LILRB2;...
Asthma -1.75 3.18e-2 25/31 (80.65%) HLA-DOA;FCER1G;CD40LG;...
Yersinia infection -1.75 3.50e-2 120/137 (87.59%) ACTR3B;GSK3B;WAS;...
Amphetamine addiction -1.79 2.72e-2 57/69 (82.61%) CREB5;ATF4;GNAS;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.81 2.77e-2 79/89 (88.76%) IKBKB;ALK;AKT1;...
Th1 and Th2 cell differentiation -1.82 2.50e-2 80/92 (86.96%) DLL3;PRKCQ;HLA-DRB1;...
T cell receptor signaling pathway -1.87 1.55e-2 93/104 (89.42%) ICOS;IKBKB;FYN;...
Rheumatoid arthritis -1.96 2.33e-3 78/93 (83.87%) CXCL12;CD86;CCL2;...
NF-kappa B signaling pathway -1.96 2.91e-3 90/104 (86.54%) ERC1;TRAF5;CD40LG;...
TNF signaling pathway -2.02 0.00e+0 103/112 (91.96%) TNFRSF1B;BCL3;CSF1;...
Hematopoietic cell lineage -2.09 0.00e+0 90/99 (90.91%) CD8B;CSF3;TFRC;...
IL-17 signaling pathway -2.17 0.00e+0 84/94 (89.36%) TRAF3;IFNG;CEBPB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12.5uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 3.33uM - 12.5uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 3.33uM - 12.5uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H